EarningsQ2 2026 Earnings Report
MX:JAZZN Q2 2026 EPS Results
Actual EPS$103.20
Consensus EPS$111.60
Beat/MissMissed by -$8.40
One Year Ago EPS-$149.11
MX:JAZZN Q2 2026 Revenue Results
Actual Revenue$21.84B
Expected Revenue$20.14B
Beat/MissBeat by +$1.70B
YoY Revenue Growth+15.55%
Earnings Announcement Details
QuarterQ2 2026
Date08/03/2026
TimeAfter Close
Conference CallMonday, August 3, 2026
MX:JAZZN Upcoming Earnings
Jazz Pharmaceuticals's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:JAZZN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and pipeline wins — record revenue, raised guidance, double-digit growth across key brands (oncology +32%, Xywav +13%, Epidiolex +16%, Zepzelca +42%) and a solid balance sheet — while acknowledging manageable margin pressure from royalties, rising SG&A/R&D investments, label adjustments for Zepzelca second-line, and potential future competitive/generic risks for the oxybate franchise. On balance, the positive execution, guidance raise, cash generation and late-stage regulatory momentum outweigh the identified challenges.Company Guidance
Record Quarterly Revenue and Raised Full-Year Guidance
Record revenue of $1.21 billion in 2Q26, up 16% year-over-year; updated 2026 revenue guidance raised to $4.60B–$4.75B driven by strong first-half performance.
Robust Oncology Growth
Oncology portfolio grew 32% year-over-year; Zepzelca net product sales $106M (up 42% YoY) with elevation to NCCN category 1 in first-line maintenance.
Zanidatamab Clinical and Regulatory Momentum (Ziihera/Zani)
PDUFA date Aug 25, 2026 for zanidatamab in first-line HER2+ metastatic GEA; NEJM publication of Phase III Horizon GEA01 data showing median OS >2 years and zanidatamab + tislelizumab arm median OS 26.4 months (~7+ months longer than control); breakthrough therapy designation granted for previously treated HER2+ colorectal cancer.
Strong Rare Sleep Performance (Xywav)
Xywav net product sales $471M in 2Q26, up 13% YoY; ~525 net patient additions in the quarter, ~17,125 active patients (~12%+ YoY growth); company now expects double-digit growth for Xywav in 2026 and rare sleep revenue of $2.025B–$2.125B.
Epidiolex Continued Momentum and Lifecycle Initiatives
Epidiolex net product sales $292M in 2Q26, up 16% YoY (12% volume growth); NDA submitted for a novel capsule formulation and multiple new trials initiated (LGS adult Phase IV, DEE Phase III, seamless Phase II/III in JME) to expand indications and adult penetration.
New Product Launch Traction and Diagnostic Progress
Ziihera (BTC) generated $15M in 2Q26 and captured >50% U.S. addressable market share in second-line BTC; Modeyso generated $48M with >600 patients treated since launch and favorable payer coverage; updated NCCN guidelines now endorse liquid biopsy for H3 K27M.
Strong Financial Position and Cash Generation
Generated $824M operating cash flow in first half of 2026; $2.2B cash on balance sheet; paid off 2026 convertible notes; delivered non-GAAP adjusted EPS of $5.71 in the quarter (included IPR&D charges of $0.94).
Pipeline Advancement and BD Activity
Phase III ACTION trial (Modeyso) on track for OS interim in H1 2027; ongoing trials across oncology (breast, CRC, NSCLC) and rare epilepsies; preclinical collaboration with AbCellera announced; management expects additional BD in 2026.
MX:JAZZN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed